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Abstract 
Purpose: To identify and report the prevalence of potential drug-drug interactions (pDDIs) in a 
neurology ward, as well as their levels and association with risk factors.  
Methods: The study was conducted in the neurology ward of Northwest General Hospital Peshawar, 
Pakistan. Medical records of 205 randomly selected patients were retrospectively reviewed for potential 
drug-drug interactions using Micromedex Drug-Reax Software.  
Results: The total number of interactions identified were 633. About 96 % of the patients showed at 
least one type of potential interaction regardless of its severity. The identified pDDIs were categorized 
on the basis of severity, scientific evidence and onset. Based on severity, of the total of 633 pDDIs, 62.2 
% were of major type while 31.8 % were of moderate type. On the basis of scientific evidence, 16.42 % 
were excellent type, 32.22 % in good category while fair category was the highest (55.60 %). The onset 
categories such as rapid (27.64 %), delayed (24.96 %) and non-specified onset (53.71 %) were also 
noted. 
Conclusion: Computerized DDIs programs are very helpful in minimizing harmful drug interactions. 
With this type of program, this better patient health outcomes can be achieved. 
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Scientific discoveries, technological 
advancements and recent developments in 
pharmacotherapy, have made a substantial 
impact in improving-the quality of patient’s-life. 
Due to such advancements in pharmacotherapy, 
a-number-of medications are available-and their 
use is increasing day by day.  The drugs-are 
capable of producing therapeutic effects on one 
hand but on other hand they can also produce 
many undesirable effects [1]. Such adverse type 
of-effects-are undesirable. Strand et al [2] has 
identified eight types of drug-related- problems. 
Amongst them the major problem is drug-drug 
interaction (DDIs). The Drug-Drug-interaction-
arises when a drug interact with another drug 
and alters or modifies its effect if administered 
together [3]. DDIs may-be beneficial or harmful. 
The harmful DDIs may lead to the adverse drug 
reactions and will leads to negative 
consequences in patients especially in 
hospitalized patients, as they usually suffer from 
severe illnesses with multiple disorders. 
Generally the term potential drug-drug interaction 
is also used in parallel, as every DDI caries the 
risk to cause negative outcomes bur are 
generally predictable which can therefore be 
avoidable or manageable [4]. 
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Owing to the importance of DDIs, the study was 
aimed to identify and to investigate the potential 
adverse outcomes in most commonly clinically 
important, potential DDIs in neurology ward in a 







This research was carried out in neurology ward 
of Northwest General Hospital & Research 
Center, Peshawar, Khyber Pakhtunkhwa, 
Pakistan.   Northwest General Hospital & 
Research center is 306 bedded tertiary care 
hospital that provides specialized health care and 
referral services to all the population in and 
around Kyber Pakhtunkhwa.  
 
Design and study population 
 
This was a cross-sectional retrospective study, 
carried out by using automated medication 
records of 205 randomly selected patients who 
had been admitted to neurology ward of hospital 
during 1 year period from 1st January, 2015 to 
31st Dec, 2015. Incomplete patients’ records 
were excluded from the study. 
 
Data collection and screening of pDDIs 
 
The study protocols complied with the guidelines 
of the Declaration of Helsinki [5,6], and the 
ethical committee of North West General 
Hospital, Peshawar granted approval (no. 
NWHP/Eth-H-087/15) for the conduct of this 
study. In-patients’ records were reviewed and 
screened retrospectively for pDDIs using 
computerized drug interaction and information 
system, the Micromedex Drug-Reax System 
(Thomson Reuters Healthcare Inc, Greenwood 
Village, Colorado, USA) [7]. 
 
The entries of all prescribed drugs to the 
selected patients from the date of admission till 
the date of discharge were made. Patients with 
major severity were screened out. Categorization 
[7] of clinically potential DDIs was made on basis 
of Onset, severity and scientific evidence. Their 




 Rapid: Onset of adverse effects or clinical 
conflict are expected to occur within 24 
hour of administration and their 
management requires immediate action. 
 
 Delayed: Onset of adverse effects or 
clinical conflict that do not appear within 24 





 Contraindicated: The drug combination is 
contraindicated for concurrent use. 
 
 Major: Such type of interactions may be 
life-threatening and fatal, require 
immediate treatment in order to prevent or 
minimize the serious negative adverse 
effects. 
 
 Moderate: Moderate interactions may 
exacerbate the patient’s condition and may 
require change in therapy. 
 
 Minor: Limited clinical effects and 





 Excellent: Controlled studies have clearly 
established the existence of the 
interaction. 
 
 Good: Documentation strongly suggests 
the existence of interaction but there is 
lack of well controlled studies. 
 
 Fair: Available documentation is poor but 
on the basis pharmacological 
considerations the interaction is suspected 
to exist and data is available from 
pharmacologically similar drug. 
 
 Poor: Documentation is very limited and 
interaction may occur theoretically, as very 
few cases are reported. 
 
 Unlikely: Documentation is very poor and 




Data was analyzed statistically by using Graph 
Pad Prism 5 (GraphPad Software Inc. San Diego 
CA, USA). The Chi-square test was used to 
analyze the data. A P value < 0.05 was defined 
as statistically significant. 
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Patient’s general characteristics 
 
In this study the potential DDIs were evaluated 
for 205 patients in neurological ward. The 
gender, age etc. details of the selected patients 
are given in Table 1. 
 











Age (years)  
≤20 38 (19) 
21-39 68 (33) 
40-59 83 (40) 
≥60 16 (08) 
Hospital stay (days)  
≤3 72 (35) 
4-6 98 (48) 




≤4 32  (146) 
5-6 74  (36) 
≥7 99  (48) 
 
Prevalence of pDDIs 
 
The total number of interactions identified were 
633. Out of 205 patients, 197 had at least one 
pDDIs regardless of type of severity. In 8 patients 
no interaction were observed.  
 
Levels of pDDIs 
 
The identified pDDIs were categorized on the 
basis of level of severity, scientific evidence and 
onset [7] and are given table 2. Among 633 
pDDIs, most of were major (394, 62.2 %) or 
moderate severity (201, 31.8 %); excellent (104, 
16.42 %) good (204, 32.22 %) or fair (352, 55.60 
%) type of scientific evidence; rapid (175, 27.64 
%) delayed (158, 24.96 %) or non-specified 
onset (340, 53.71 %) 
 
Commonly interacting combinations 
 
About 69 interacting pairs were identified in this 
study. There were top 15 major frequently 




This study-represents the importance of 
computer software program for checking the 
potential DDIs. About 633 drug interactions were 
identified from clinical records of 205 hospitalized 
patients admitted in neurology ward, in which 96 
% patients showed at least one potential drug-
drug interaction during hospitalization regardless 
of severity of the interaction.  
 
Most of pDDIs were of major severity type (62.2 
%) and were of serious concern. Medically they 
are of prime importance for practitioners as they 
produces negative outcomes. Co-administration 
with carbapenem antibiotics may substantially 
decrease-the concentrations of-valproic-acid in 
serum. However simultaneous use of valproic 
acid with carbapenem is generally not 
recommended [8]. There is risk of epidural or 
spinal-hematoma if Aspirin and Enoxaparin 
combination is used in patients receiving 
neuraxial-anesthesia or spinal-puncture [9]. 
While using haloperidol and tramadol 
combination, one must be cautious, as it can 
reduce the seizure threshold and thus there is an 
increased risk of seizures [10]. 
 
 
Table 2: Distribution of identified potential drug-drug interactions on the basis of Levels 
 
Level N % x2 P-value 
Severity     
Contraindicated 021 03.32   
Major 394 62.24 607.866 <0.001 
Moderate 201 31.75   
Minor 017 02.68   
Documentation     
Excellent 104 16.43   
Good 204 32.22 141.527 <0.001 
Fair 352 55.61   
Onset     
Rapid 165 26.06   
Delayed 158 24.96 96.226 <0.001 
Non specified 340 53.71   
Chi-square test was used and p < 0.05 was considered statistically significant 
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Table 3: Identified potential drug-drug interactions and their adverse out comes 
 
Interaction  n Severity Onset Evidence Potential adverse outcomes 
Meropenem + valproic 
Acid 
58 Major Rapid  Excellent Loss of seizure control 
Tramadol + 
Metoclopramide 
56 Major Not 
Specified 
Fair Increase the risk for seizure. 
Haloperidol + Tramadol 48 Major Rapid Fair Increase the risk for seizure. 
Aspirin + Enoxaparin 43 Major Not 
Specified 
Fair Increase the risk for bleeding. 
Clopidogrel + Enoxaparin 37 Major Not 
Specified 
Fair Increase the risk for bleeding. 
Diazepam + Phenytoin 32 Major Not 
Specified 
Good Results in altered serum phenytoin 
concentration 
Tramadol + Linezolid 22 Major Not 
Specified 
Good Increase the risk of Serotonin 
syndrome. 
Aspirin + Clopidogrel 19 Major Not 
Specified 
Fair Increase the risk of bleeding. 
Diclofenac + Enoxaparin 17 Major Not 
Specified 
Good Increase the risk of bleeding. 
Heparin + Aspirin 10 Major Not 
Specified 
Fair Increase the risk of bleeding. 
Enoxaparin + Warfarin 10 Major Not 
Specified 
Fair Increase the risk of bleeding. 
Escitralopram + Tramadol 7 Major Not 
Specified 
Fair Increase the risk of seizures, serotonin 
syndrome, opioid toxicity and Increase 
concentration of tramadol. 
Ciprofloxacin + 
Prochlorperazine 
5 Major Not 
Specified 
Fair Increase risk of QT interval 
prolongation. 
Valproic Acid + Imepenem 5 Major Not 
Specified 
Good Loss of anticonvulsant effect due to 
decrease valproic Acid concentration. 
Amikacin + Colistimethate 3 Major Rapid Fair Causes Respiratory depression. 
 
Similarly, the co-administration of diazepam and 
phenytoin results in phenytoin toxicity [11]. The 
intake of linzolid with such medicines that results 
in increased concentrations of serotonin in the 
central nervous system may lead to Serotonin 
toxicity [12]. The combination of anticoagulants 
and NSAID would increase the peri-operative risk 
of bleeding problems [13]. 
 
There are many drug-drug interactions 
compendia which have been classified on the 
basis of their levels of severity, onset, evidence 
based scientific literatures, management-options-
or-their-combinations [9,14,15]. 
 
The incidence of DDIs in different countries 
varies from 6% to 70% due to variability in 
methodologies and settings. These variations 
arises due differences in design of research 
studies, locations of study (e.g., hospitals, 
emergency rooms, community settings, nursing 
homes), population’s characteristics (e.g., 
elderly, adults), availability of advanced clinical 
pharmacy services and the most important, 
accessibility and use of electronic DDIs. 
Screening programs. Hospitalized patients 
usually suffer from severe illnesses and multiple 
disorders as compared to community and 
outpatient settings. Due to this reason, DDIs-are-
less likely-to-occur in outdoor patients or 
community setups as compared to hospitalized 
patients. Therefore their negative outcomes 
would be-more-severe in admitted patients. 
Generally-large-number of medications-are-
prescribed to admitted patients. Due to complex-
therapeutic regimens, DDIs need more attention 
in hospitalized patients.  
 
Advanced computer software systems are now 
available, with the aid of which, pDDIs can be 
easily identified and managed by replacing a 
particular drug with another related one, by 
altering the dose amount or by close monitoring 
the clinical signs and laboratory test outcomes 
[7-15]. Pharmacists can optimize the 
pharmacotherapy by applying their professional 
knowledge, skills and using the computerized 
scientific evidence based software programs, 
which would be helpful to minimize or prevent the 
serious negative consequences of DDIs [16,17]. 
These results suggest that these patients are at 
higher risk to negative consequences of these 
identified drug interactions therefore patients’ 
clinical conditions needs very careful and close 
monitoring. 
 
Limitations of the study 
 
Although there much work remains to be done, 
and important findings have been generated in 
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this study, it was limited to only those patients 
admitted in the neurology ward of the hospital. 
To obtain a clearer picture of the drug-drug 
interaction, data for out-patients are also needed. 




Comparatively high numbers of incidence of 
pDDIs (major severity) were recorded in the 
neurology ward of the study site. To avoid the 
negative consequences of pDDIs, computational 
software are helpful tools but their successful use 
is tied to medical experience, knowledge of 
relevant patient-related factors as well as 
establishment of drug information centers. The 
identified pDDIs in this study are of serious 
nature and are harmful to patients. Therefore, the 
medication orders should be screened and 
analyzed by a clinical pharmacist, at least for 
major DDIs, before the mediation is dispensed. 
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